REGELKRAVEU PPWR Art. 7 - 30% rPET in contact-sensitive packaging by 2030 · CA AB 793 - 25% PCR in bottles by 2025 · CA SB 54 - 65% by 2032Alla regelverk →
NEXAMINSIGHTSINTE KOPPLAT TILL NEXAM CHEMICAL AB
NEXAM2.70 SEK ≈ $0.27
MKT CAP 305 MSEK ≈ $31MSHARES 102,662,09252W 2.18 - 4.08 SEK ≈ $0.22 - 0.41NASDAQ FIRST NORTH

Library · High-temp · GUIDE

Medical-Grade Polymer Additives & Color Masterbatches

Updated Read 3 minEN · SV · +19

The previous site claimed a medical-grade product line. We checked the company's own pages and found none, so this page records what we looked for and what the category would require.

This entry exists because the previous version of this site claimed a medical-grade product line for Nexam Chemical. We went looking for it and could not find one. Rather than delete the page and leave the question hanging, here is what we checked, what we found, and what the category would require if the company ever entered it.

What we checked

We read the company's product index and every product page, all eight application pages, the about and investor pages, and its press releases back to early 2024. The words medical, medical-grade, healthcare, pharma and pharmaceutical do not appear in any of them. There is no additive, masterbatch or color concentrate presented for medical devices or pharmaceutical packaging.

The nearest adjacent claim is food contact, not medical: the company states that its PET grade M021200 is epoxy-free and food-contact compliant, and a March 2026 release describes a United States customer in rigid food packaging. Food contact and medical are different regulatory worlds, and one does not imply the other.

A page that says "we checked and it is not there" is more useful than a page that repeats a claim nobody can source. The previous version of this entry described a medical-grade offering in detail. None of it survived checking.

Why the category is hard to enter

Medical is not simply a stricter version of food contact. Three things make it a different business:

  • Qualification is per device, not per material. A polymer additive is qualified as part of a finished device's submission, so the customer carries the regulatory burden and will not change a qualified formulation casually.
  • Biocompatibility testing under the ISO 10993 series is required for the finished device in contact with the body, which means an additive supplier has to support a customer's testing rather than certify its own product into the application.
  • Recycled content is largely absent. Medical packaging and devices are dominated by virgin material for traceability reasons, which removes exactly the argument that drives the company's recycling business.

The result is long qualification cycles, small volumes per program, and high switching costs once a supplier is in. It is an attractive business to hold and an expensive one to enter.

What would have to be true

If Nexam Chemical did enter medical, the signs would be visible before the revenue: a named product page with regulatory documentation, a partnership with a device or packaging manufacturer, or a statement in an interim report. None of those exist today. The company's current direction, judged by its own announcements, is recycling applications, distribution agreements and production capacity in Europe and North America.

What this page will become

If a medical offering appears, this entry becomes a guide to it, with the documentation. Until then it stands as a record of a claim that did not hold up. If you know of a Nexam product in medical applications that we have missed, tell us and we will correct this page in public, with the source.

Sources

Independent research, not affiliated with Nexam Chemical and not investment advice.